- Home
- AIP vs AVIR Comparison
AIP vs AVIR Comparison
Compare AIP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIP | AVIR |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 767.5M | 450.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AIP | AVIR |
|---|---|---|
| Price | $17.55 | $5.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $16.83 | $8.00 |
| AVG Volume (30 Days) | 399.0K | ★ 571.5K |
| Earning Date | 05-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $70,579,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $30.24 | N/A |
| Revenue Next Year | $19.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.27 | N/A |
| 52 Week Low | $5.64 | $2.46 |
| 52 Week High | $19.85 | $6.45 |
Technical Indicators
Market Signals| Indicator | AIP | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 58.02 | 57.90 |
| Support Level | $15.10 | $3.33 |
| Resistance Level | $19.85 | $6.45 |
| Average True Range (ATR) | 1.09 | 0.27 |
| MACD | 0.13 | -0.10 |
| Stochastic Oscillator | 72.86 | 56.47 |
Price Performance
Historical ComparisonAbout AIP Arteris Inc.
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.